OS Fund

Type

Venture Capital

Status

Active

Location

Chicago, United States

Total investments

48

Average round size

21M

Portfolio companies

34

Rounds per year

4.80

Lead investments

6

Follow on index

0.29

Exits

5

Areas of investment
BiotechnologyArtificial IntelligenceMachine LearningHealth CareHealth DiagnosticsGeneticsRoboticsMedicalLife ScienceTherapeutics

Summary

This organization was formed by Bryan Johnson, Jeff Klunzinger, Jeffrey Klunzinger. We also calculated 4 valuable employees in our database.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the OS Fund, startups are often financed by Founders Fund, Data Collective DCVC, Y Combinator. The meaningful sponsors for the fund in investment in the same round are Y Combinator, Founders Fund, Data Collective DCVC. In the next rounds fund is usually obtained by Y Combinator, Lux Capital, Data Collective DCVC.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Genetics. The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Cleversafe, Human Longevity, Ginkgo BioWorks.

The top amount of exits for fund were in 2018. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. Opposing the other organizations, this OS Fund works on 22 percentage points less the average amount of lead investments. Speaking about the real fund results, this VC is 3 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 7-12 investment rounds annually. The average startup value when the investment from OS Fund is 100-500 millions dollars.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcareMedtech
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 250000000
Fund raised date
2018-08-07

Analytics

Total investments
48
Lead investments
6
Exits
5
Rounds per year
4.80
Follow on index
0.29
Investments by industry
  • Biotechnology (31)
  • Health Care (18)
  • Health Diagnostics (10)
  • Genetics (8)
  • Medical (8)
  • Show 62 more
Investments by region
  • United States (44)
  • Canada (4)
Peak activity year
2016
Number of Unicorns
3
Number of Decacorns
3
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
262M
Group Appearance index
0.94
Avg. company exit year
8
Avg. multiplicator
6.21
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
01 Jan 2018 Automotive, Infrastructure, Software, Artificial Intelligence, Developer Tools, Developer Platform, Blockchain, Developer APIs, Advanced Materials, Nanotechnology Seed 0 United States, San Francisco
Kenota Health 22 Aug 2016 Biotechnology, Health Care, Health Diagnostics, Medical Seed Ontario, Kitchener, Canada
Ginkgo Bioworks 18 Mar 2015 Biotechnology, Chemical, Biopharma Early Stage Venture 9M United States, Massachusetts, Boston
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.